You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《瑞信窩輪》藥股回軟玖紙急跌,留意石藥沽25458、玖龍購19939
阿思達克 09-25 13:26

內地藥品帶量採購結果公布,產品均價跌幅擴大,醫藥股回軟。

周二曾倒升逾9%的龍頭藥股石藥集團(1093),周三曾跌逾4%,險守15.5元水平。看好可考慮石藥購13837,行使價16.88元,19年12月到期。相反看淡可留意石藥沽25458,行使價13.28元,20年3月到期。或石藥熊64453,收回價17.88元,行使價18.58元,20年1月到期。

中國生物製藥(1177)周三更曾穿10元,跌幅一度超過半成。看好可考慮中藥購23888,行使價12.68元,20年2月到期。相反看淡可留意中藥沽24621,行使價9.08元,20年3月到期。

美國總統特朗普抨擊中國貿易政策不公,貿戰敏感股周三捱沽。在美國有豬肉業務的食品股萬洲國際(0288),周三曾跌逾4%,低見6.8元以下。看好可留意貼價萬洲購26566,行使價6.89元,19年12月到期。相反看淡則可留意貼價萬洲沽20274,行使價6.85元,19年12月到期。出口股創科實業(0669)周三曾挫逾2%至52元,看好可留意創科購21613,行使價66.38元,20年7月到期。

汽車股吉利汽車(0175)周三跟隨大市偏軟,低位曾跌逾2%,險守12.5元。看好可留意吉利購21053,行使價14.90元,20年4月到期。或50兌1吉利牛55684,收回價12.08元,行使價11.58元,20年9月到期。相反看淡可留意吉利沽25419,行使價11.08元,20年3月到期。或50兌1吉利熊56203,收回價14.08元,行使價14.58元,20年6月到期。

玖龍紙業(2689)公布,全年少賺逾五成,股價周三曾挫逾7%,一度低見6.3元以下。觀望反彈,可留意玖龍購19939,行使價6.88元,20年4月到期。

(本結構性產品並無抵押品)

《瑞信香港認股證及牛熊證銷售主管何啟聰》

免責聲明:筆者為瑞士信貸(香港)有限公司的代表 ,並身為證監會持牌人,並無持有相關上市公司的任何財務權益。本文內容僅供參考,並不構成要約、建議或促使任何人士提呈買賣或認購任何證券。結構性產品價格可急升或急跌,投資者或會蒙受全盤損失。本產品並無抵押品。如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。牛熊證備強制贖回機制而可能被提早終止,屆時(i)N類牛熊證投資者將不獲發任何金額;而(ii)R類牛熊證之剩餘價值可能為零。有關恆生指數或恆生中國企業指數的免責聲明,請參閱上市文件。過往表現並不反映將來表現。投資前,投資者應瞭解風險,並諮詢專業顧問及查閱有關上市文件。瑞信之聯屬公司為結構性產品之流通量提供者,亦可能是唯一報價者。本文任何內容概不構成投資、法律、會計或稅務意見、並無聲明任何投資或策略適合或符合閣下的個別情況。結構性產品交投量並不是結構性產品表現的指標,投資者不應僅依賴交投量歷史高位數據以釐定結構性產品日後的表現。~重要聲明:

以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account